×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATOS – atossa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
09:12 am
atos
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
3/26
08:19 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/25
08:18 am
atos
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/25
08:00 am
atos
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
3/20
09:13 am
atos
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
3/12
08:05 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/11
08:15 am
atos
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Medium
Report
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
2/5
08:00 am
atos
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Low
Report
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Date
Time
Symbol
Headline
Impact
4/7
04:05 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Apr 07
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Apr 07
3/28
04:00 pm
atos
Form 4 ATOSSA THERAPEUTICS, For: Mar 26 Filed by: Remmel H. Lawrence
Medium
Report
Form 4 ATOSSA THERAPEUTICS, For: Mar 26 Filed by: Remmel H. Lawrence
3/26
04:40 pm
atos
Form ARS ATOSSA THERAPEUTICS, For: Dec 31
Low
Report
Form ARS ATOSSA THERAPEUTICS, For: Dec 31
3/26
04:30 pm
atos
Form DEF 14A ATOSSA THERAPEUTICS, For: Mar 26
Low
Report
Form DEF 14A ATOSSA THERAPEUTICS, For: Mar 26
3/25
08:10 am
atos
Form 10-K ATOSSA THERAPEUTICS, For: Dec 31
Medium
Report
Form 10-K ATOSSA THERAPEUTICS, For: Dec 31
3/25
08:05 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Mar 25
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Mar 25
3/12
09:00 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Mar 11
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Mar 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
22.9%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
TOP News Decliners
4/16
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
-26.0%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: